Giannella E, Mochmann H C, Levi R
Department of Pharmacology, Cornell University Medical College, New York, NY 10021, USA.
Circ Res. 1997 Sep;81(3):415-22. doi: 10.1161/01.res.81.3.415.
We previously reported that hypoxic coronary vasodilatation (HCVD) is initiated by endothelial NO and sustained by adenosine. Prolonged ischemia/reperfusion impairs endothelium-dependent coronary vasodilatation, whereas transient ischemia (ie, preconditioning) protects the myocardium from subsequent ischemic events. Accordingly, we assessed whether prolonged ischemia/reperfusion impairs HCVD and whether preconditioning prevents this dysfunction. HCVD, elicited in isolated guinea pig hearts by a 1-minute exposure to 100% N2, consisted of an approximately 70% increase in coronary flow associated with enhanced nitrite/nitrate and adenosine overflow (+40% and 5-fold, respectively). After 30-minute global ischemia and 20-minute reperfusion, HCVD was decreased by approximately 60%, and the increases in nitrite/nitrate and adenosine overflow were abolished. Preconditioning (ie, three cycles of 5-minute global ischemia+5-minute reperfusion) prevented the impairment of HCVD and fully restored the increase in nitrite/nitrate overflow, but not that of adenosine. The protective effect of preconditioning was mimicked by perfusion with the adenosine A1 receptor agonist N6-cyclopentyladenosine and prevented by the A1 receptor antagonist N-0861. In addition, the A3 receptor agonist N6-(3-iodobenzyl)adenosine-5'-N-methyl-carboxamide had a similar protective effect. The bradykinin B2 receptor antagonist HOE 140 abolished the protective effect of preconditioning, whereas the NO synthase inhibitor N(omega)-methyl-L-arginine and the cycloxygenase inhibitor indomethacin did not. Our data indicate that preconditioning restores HCVD by a process that is triggered by activation of adenosine A1/A3 and bradykinin B2 receptors. The action of bradykinin is independent of NO and prostacyclin production. Once restored by preconditioning, HCVD is mediated by NO but no longer sustained by adenosine.
我们之前报道过,缺氧性冠状动脉血管舒张(HCVD)由内皮型一氧化氮启动,并由腺苷维持。长时间的缺血/再灌注会损害内皮依赖性冠状动脉血管舒张,而短暂性缺血(即预处理)可保护心肌免受随后的缺血事件影响。因此,我们评估了长时间的缺血/再灌注是否会损害HCVD,以及预处理是否能预防这种功能障碍。在分离的豚鼠心脏中,通过暴露于100%氮气1分钟引发的HCVD,表现为冠状动脉血流增加约70%,同时亚硝酸盐/硝酸盐和腺苷溢出增加(分别增加40%和5倍)。在30分钟全心缺血和20分钟再灌注后,HCVD降低了约60%,亚硝酸盐/硝酸盐和腺苷溢出的增加被消除。预处理(即5分钟全心缺血+5分钟再灌注的三个周期)可预防HCVD的损害,并完全恢复亚硝酸盐/硝酸盐溢出的增加,但不能恢复腺苷的增加。腺苷A1受体激动剂N6-环戊基腺苷灌注可模拟预处理的保护作用,而A1受体拮抗剂N-0861可阻止这种作用。此外,A3受体激动剂N6-(3-碘苄基)腺苷-5'-N-甲基甲酰胺具有类似的保护作用。缓激肽B2受体拮抗剂HOE 140可消除预处理的保护作用,而一氧化氮合酶抑制剂N(ω)-甲基-L-精氨酸和环氧化酶抑制剂吲哚美辛则不能。我们的数据表明,预处理通过腺苷A1/A3和缓激肽B2受体激活触发的过程恢复HCVD。缓激肽的作用独立于一氧化氮和前列环素的产生。一旦通过预处理恢复,HCVD由一氧化氮介导,但不再由腺苷维持。